IgA Nephropathy in Pediatric Patients

EP: 1.An overview of IgA Nephropathy

EP: 2.IgA Nephropathy in Different Ethnic Populations

EP: 3.IgA Nephropathy in the Transplant Population

Now Viewing

EP: 4.IgA Nephropathy in Pediatric Patients

EP: 5.An Overview of C3G

EP: 6.C3G in Pediatric Patients

EP: 7.Challenges of Managing C3G

EP: 8.Consequences of a Late or Missed Diagnosis of C3G

EP: 9.Differential Diagnosis of C3G

EP: 10.The Pathology of IgAN on Kidney Biopsy

EP: 11.The role of electro microscopy in the diagnosis of IgAN

EP: 12.Kidney biopsy as a guide for treatment and prognosis

EP: 13.Diagnostic testing in C3G

EP: 14.Diagnosing C3G in pediatric patients

EP: 15.Kidney biopsy C3G

EP: 16.Building expertise in C3G

EP: 17.Clues to C3G in a biopsy

EP: 18.Barriers to kidney biopsy

EP: 19.Current standard of care for C3G

EP: 20.Clinical trial data on complement inhibition in C3G

EP: 21.Complement therapy in transplant patients in C3G

EP: 22.Clinical trial data on IgAN for therapies

Jonathan Barratt, PhD, FRCP: Carla, I'm often fascinated by children because to me they're completely different levels. And I'd be interested in your experience of how IgA nephropathy presents and differs or is the same in fact between adults and children?

Carla M. Nester, MD, MSA, FASN: Well, in fact, I could say it's very similar to what Dr Appel has presented in that there can be asymptomatic children but there can also be children with very aggressive disease. And the problem is, determining who that's going to be and whether supportive care is going to support them long enough. Let's face it. Children have double, quadruple many, many more years of native kidney disease that we have to try to achieve success with, and it's just very difficult to find that right now. They do present with infection like we already mentioned. What do you do with them? How aggressive can you be with them? Right now, we just don't have the therapies to be aggressive with them. It's an important direction for us to be considering our next step in research, frankly.

Jonathan Barratt, PhD, FRCP: Absolutely. And with all the new therapies that are currently being evaluated in adults, it will be lovely to see those translated through to pediatric practice.

Transcript Edited for Clarity